We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) ended the recent trading session at $49.11, demonstrating a -2.68% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow gained 0.05%, and the Nasdaq, a tech-heavy index, added 0.91%.
The medical device manufacturer's stock has dropped by 11.71% in the past month, falling short of the Medical sector's gain of 2.82% and the S&P 500's gain of 4.96%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.41 billion, up 6.82% from the year-ago period.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $21.67 billion. These results would represent year-over-year changes of +10.13% and +7.95%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.09% decrease. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 14.96. This valuation marks a discount compared to its industry average Forward P/E of 18.52.
We can also see that BSX currently has a PEG ratio of 0.93. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.52.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Boston Scientific (BSX - Free Report) ended the recent trading session at $49.11, demonstrating a -2.68% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow gained 0.05%, and the Nasdaq, a tech-heavy index, added 0.91%.
The medical device manufacturer's stock has dropped by 11.71% in the past month, falling short of the Medical sector's gain of 2.82% and the S&P 500's gain of 4.96%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.41 billion, up 6.82% from the year-ago period.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $21.67 billion. These results would represent year-over-year changes of +10.13% and +7.95%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.09% decrease. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 14.96. This valuation marks a discount compared to its industry average Forward P/E of 18.52.
We can also see that BSX currently has a PEG ratio of 0.93. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.52.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.